Nephrocare Health Services
- Market cap
- ₹ 5,991 Cr.
- P/E
- 74.2x
- P/B
- 5.41x
- 52-week range
- 446 – 781.5
- ROE
- 9%
- ROCE
- 15%
- Debt / equity
- 0.07
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- NSE, BSE
About
Nephrocare Health Services Limited, formerly Nephrocare Health Services Pvt Ltd, is an India-based company. The Company is primarily engaged in the business of providing dialysis and sale of related healthcare services and products. The Company offers comprehensive dialysis care through the network of clinics from diagnosis to treatment and wellness programs including hemodialysis, home and mobile dialysis, supported by a pharmacy. It has a network of approximately 490 clinics, with 43 clinics internationally across the Philippines, Uzbekistan and Nepal. Its subsidiaries include Nephrocare Health Services Central Asia FE LLC, Nephrocare Health Services International Pte. Ltd, Nephrocare Health Services Nepal Private Limited, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Nephrocare Health Services against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)74.2 against a typical 21: pricier than most peers (1st = cheapest).28th of 34
- Sales growth+23.7% against a typical +19.1% from a year earlier.10th of 31
- Profit growth+33.3% against a typical +25.2% from a year earlier.9th of 24
- Share price, 3 months−11.3% against a typical −7.7%.22nd of 33
- Size₹ 5,991.5 Cr. market value against a typical ₹ 83 Cr. (1st = largest).5th of 34
Latest announcements
Exchange filings and their impact on the company.
- Philippines arm to acquire assets of one dialysis center in Quezon City; price undisclosed, impact tiny.
Nephrocare Health Services said its overseas step-down subsidiary in the Philippines signed an Asset Transfer Agreement on October 27, 2026 with JCM Summit Health Inc. to acquire identified assets of a dialysis center at Don Mariano Marcos Avenue, Quezon City. The company said the deal exceeds its materiality threshold but did not disclose the consideration, citing commercial sensitivity. It is a single-center addition to NephroPlus's network, implying only a marginal lift to revenue and profit over the next year.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by India Ratings- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND AA-; IND A1+ | Stable | 18 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 18 Sep 2026 | ▲ Upgrade | IND AA- | — | India Ratings | ₹ 226.23 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 11 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 19 May 2026 | Financial Results | To consider and approve the audited financial results for the quarter and financial year ended March 31, 2026 |
| 10 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 197 | 219 | 228 | 246 | 260 | 266 | 282 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 | 221 |
| Operating Profit | 44 | 51 | 48 | 64 | 61 | 51 | 60 |
| OPM % | 22% | 23% | 21% | 26% | 23% | 19% | 21% |
| Other Income | 5 | 4 | 7 | 4 | 3 | 12 | 7 |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 | 2 |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 | 25 |
| Profit before tax | 26 | 30 | 29 | −1 | 36 | 33 | 41 |
| Tax % | 24% | 17% | 17% | 1,427% | 11% | 9% | 22% |
| Net Profit | 20 | 25 | 24 | −9 | 32 | 30 | 32 |
| EPS in Rs | 96.5 | 119.3 | 13.1 | −5.24 | 3.21 | 3.03 | 3.19 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 28%
- 3 Years
- 32%
- TTM
- 32%
- 10 Years
- —
- 5 Years
- 162%
- 3 Years
- 103%
- TTM
- 12%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 6%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Nephrocare Health Services | ₹ 626.00 | ₹ 5,991 Cr. | 74.2x | 5.4x | 9% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Vikram Vuppala
- Executive Chairman, Managing Director
- Rohit Singh
- Group Chief Executive Officer
- Prashant Vinodkumar Goenka
- Chief Financial Officer, Chief Risk Officer
- Kishore Kathri
- Company Secretary, Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.